Analysts Anticipate Allena Pharmaceuticals Inc (ALNA) to Post ($0.33) Earnings Per Share

Shares of Allena Pharmaceuticals Inc (NASDAQ:ALNA) have been given a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy rating.

Brokerages have set a 1-year consensus price target of $26.00 for the company and are anticipating that the company will post ($0.33) EPS for the current quarter, according to Zacks. Zacks has also assigned Allena Pharmaceuticals an industry rank of 158 out of 265 based on the ratings given to related companies.

ALNA has been the topic of several recent research reports. Credit Suisse Group initiated coverage on Allena Pharmaceuticals in a research report on Monday, November 27th. They set an “outperform” rating and a $22.00 price objective on the stock. Jefferies Group initiated coverage on Allena Pharmaceuticals in a research report on Monday, November 27th. They set a “buy” rating and a $22.00 price objective on the stock. Cowen initiated coverage on Allena Pharmaceuticals in a research report on Monday, November 27th. They set an “outperform” rating on the stock. Finally, Wedbush initiated coverage on Allena Pharmaceuticals in a research report on Monday, November 27th. They set an “outperform” rating and a $30.00 price objective on the stock.

In related news, Director James N. Topper purchased 500,000 shares of the firm’s stock in a transaction that occurred on Monday, November 6th. The shares were bought at an average price of $14.00 per share, for a total transaction of $7,000,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Bessemer Venture Partners Vii purchased 36,000 shares of the firm’s stock in a transaction that occurred on Monday, November 6th. The stock was bought at an average price of $14.00 per share, for a total transaction of $504,000.00. The disclosure for this purchase can be found here.

Allena Pharmaceuticals (NASDAQ:ALNA) traded down $0.08 during mid-day trading on Tuesday, reaching $10.65. The company’s stock had a trading volume of 55,000 shares, compared to its average volume of 71,167. The company has a current ratio of 4.83, a quick ratio of 4.83 and a debt-to-equity ratio of -0.09. Allena Pharmaceuticals has a 1 year low of $8.66 and a 1 year high of $15.40.

TRADEMARK VIOLATION NOTICE: This piece was first published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://transcriptdaily.com/2018/01/05/analysts-anticipate-allena-pharmaceuticals-inc-alna-to-post-0-33-earnings-per-share.html.

Allena Pharmaceuticals Company Profile

Allena Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones.

Get a free copy of the Zacks research report on Allena Pharmaceuticals (ALNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply